Dentatorubral-Pallidoluysian Atrophy: An Update by Carroll, Liam S. et al.
Reviews
Dentatorubral-pallidoluysian Atrophy: An Update
Liam S. Carroll
1




& Kathryn J. Peall
4*
1Department of Neurology, Wessex Neurological Centre, Southampton General Hospital, Southampton, UK, 2MRC Centre for Neuropsychiatric Genetics and
Genomics, Cardiff University, Cardiff, UK, 3University Hospital of Wales, Cardiff and Vale University Health Board, Health Park, Cardiff, UK, 4Neuroscience and
Mental Health Research Institute, Cardiff University, Cardiff, UK
Abstract
Background: Dentatorubral-pallidoluysian atrophy (DRPLA) is a rare, autosomal dominantly inherited disorder characterized by myoclonus, epilepsy, ataxia,
and dementia. Diagnosis is challenging due to the heterogeneous presentation and symptomatic overlap with other spinocerebellar ataxias. Symptoms vary
according to age of onset, with a mean age at onset of 31 years. A CAG repeat expansion in the ATN1 gene results in neuronal intranuclear inclusions, variable
neuronal loss, and astrocytosis in the globus pallidus, dentate and red nuclei. No disease-modifying or curative treatments are currently available
Methods: We performed an online literature search using PubMed for all articles published in an English Language format on the topics of DRPLA or ATN1 over
the last 10 years. Where these articles cited other research as support for findings, or statements, these articles were also reviewed. Contemporary articles from
related research fields (e.g., Huntington’s Disease) were also included to support statements.
Results: Forty-seven articles were identified, 10 were unobtainable and 10 provided no relevant information. The remaining 27 articles were then used for the
review template: seven case reports, seven case series, six model system articles (one review article), four population clinical and genetic studies (one review article),
two general review articles, and one human gene expression study. Other cited articles or research from related fields gave a further 42 articles, producing a total of
69 articles cited: 15 case series (including eight family studies), 14 model systems (one review article), 14 population clinical and genetic studies (two review articles),
10 case reports, eight clinical trials/guidelines, four genetic methodology articles, three general review articles, and one human gene expression study.
Discussion: DRPLA remains an intractable, progressive, neurodegenerative disorder without effective treatment. Early recognition of the disorder may improve
patient understanding, and access to services and treatments. Large-scale studies are lacking, but are required to characterize the full allelic architecture of the
disorder in all populations and the heterogeneous phenotypic spectrum, including neuroimaging findings, possible biomarkers, and responses to treatment.
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Introduction
Dentatorubral-pallidoluysian atrophy (DRPLA) (OMIM 125370) is
characterized by symptoms such as myoclonus, epilepsy, ataxia,
choreoathetosis, and dementia that are variable.1,2 DRPLA is one of
a group of autosomal dominant, hereditary ataxias, and is caused by
a CAG trinucleotide repeat expansion (>48 tandem copies) in the
Atrophin-1 (ATN1) gene.3–5 DRPLA was initially recognized in Asian
populations, although wider genetic testing has increased diagnosis in
other ethnic groups.6–8 Clinical presentation is frequently hetero-
geneous and typically varies dependent on age at onset: younger onset
individuals often present with seizures, and older individuals more
commonly present with ataxia and cognitive impairment. Clinical
symptoms are progressive, with life expectancy typically 8–16 years
from symptom onset.1,9 At present, no disease-modifying or curative
therapies exist, with current treatment paradigms involving supportive
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care provided by multidisciplinary teams.3,10 As a rare disorder there
are a lack of publications: only two general review articles (published in
2010 and 2016)1,2 and no systematic review articles. This systematic
review provides an update of the understanding of the clinical pheno-
type, underlying disorder molecular and mechanistic pathophysiology,
and future therapeutic direction.
Methods
We performed a systematic literature search of the PubMed database
using the key words ‘‘DRPLA’’, ‘‘dentatorubral-pallidoluysian atrophy’’,
‘‘ATN1’’, and ‘‘Atrophin 1’’ (Table 1). All articles published in English
and in peer-reviewed journals, print or online books over the last 10 years
were included. We also checked the reference lists of each relevant study
that resulted from this search for further appropriate articles. Older
articles and research articles from other fields were also cited where
appropriate to support findings or statements. Forty-seven articles
were identified of which we were able to access 37. Of the 37 articles,
10 were excluded due to lack of relevance to the clinical or molecular
pathological aspects of DRPLA, resulting in 27 remaining articles.
Supportive articles cited within these 27 core articles were also reviewed
and included, together with contemporary research from DRPLA rela-
ted fields (e.g., Huntington’s disease [HD]), giving a total of 69 articles
included in this review (Figure 1). The articles are 15 case series
(including eight family studies), 14 model systems (one review article),
14 population clinical and genetic studies (two review articles), 10 case
reports, eight clinical trials/guidelines, four genetic methodology articles,
three general review articles, and one human gene expression study.
Case descriptions
Here we provide two examples of clinically typical younger- and
older-onset cases
Older-onset case
A 31-year-old Caucasian male presented to the neurology out-
patient clinic with a 2-year history of progressive gait disturbance,
principally manifesting as unsteadiness and difficulty with balance.
More recently he had begun to fall and had started to use a single stick
for support when outside the home. In addition to this, his partner had
also commented that he was generally more fidgety than normal, with
a tendency to move his hands and feet involuntarily when watching the
television. He had no past medical history of note and was taking no
regular medication. He drank occasionally, was a non-smoker, and
had never used recreational drugs. There was a family history of
similar symptoms, with both his father and paternal uncle developing
atypical movements and memory impairment in their mid-30s,
progressing to being wheelchair bound by their early 40s. On exami-
nation there was evidence of subtle choreiform movements involving
the limbs and perioral region. There was a full range of pursuit eye
movements, although saccades were impaired, and there was evidence
of both vertical and horizontal nystagmus. Finger–nose, heel–shin, and
tandem gait testing revealed clear evidence of cerebellar ataxia. Sub-
sequent investigations included, among other tests, cerebral magnetic
resonance imaging (MRI) that demonstrated atrophy of the cerebellum,
and to a lesser extent the basal ganglia. Given the family history, genetic
testing was undertaken, which initially included the spinocerebellar
ataxias (SCA1, 2, 3, 6, 7, and 17) and HD. No mutation was identified
with these tests, leading to subsequent testing of the ATN1 gene.
Younger-onset case
A 12-year-old female presented to her local emergency department
with a sustained generalized seizure, having no prior reported seizure
history, and was not taking any regular medication at the time. She
was currently under long-term review with a local pediatrician because
of some evidence of delayed developmental milestones during early
childhood, and more recently the development of disruptive behavior
in the classroom, as well as progressive difficulties with academic work.
Her mother also described infrequent episodes that may have been
consistent with visual hallucinations. The patient had no ongoing contact
with her father, but her mother was aware of a paternal family history of
dementia and progressive gait difficulties. Following post-ictal recovery,
the patient was generally found to be withdrawn with a reluctance to
engage in the examination. There were occasional brief jerks, consistent
with a spontaneous myoclonus, predominantly visible with outstretched
arms. The only other clinical finding of note was disrupted horizontal
saccades during eye movement examination. Brain MRI demonstrated
evidence of a few periventricular white matter hyperintensities, visible
bilaterally, but no marked focal atrophy. Subsequent investigation of
the family history found that her father had been found to have a
CAG repeat expansion (65 repeats) of the ATN1 gene.
Results
Clinical findings
DRPLA has a median age at onset of 31 years of age and demon-
strates no sex bias, affecting males and females equally. Ataxia and
cognitive impairment are cardinal features of the disorder; however,
age at onset affects clinical presentation.1,6,9 Typical clinical features of
adult-onset disease (>20 years of age) include ataxia, cognitive impair-
ment, and choreoathetosis with median age at onset for these presen-
tations of 38–43 years.1,6,9 Epilepsy and intellectual disability are more
common in those with juvenile-onset symptoms, with epilepsy having a
median age at onset of 15–19 years, dependent upon the study.7,9,11
This clinical separation is also observed in juvenile-onset and adult-
onset HD, where the juvenile onset form tends to present with rigidity,
seizures, and cognitive decline as opposed to the chorea that is the
hallmark of the adult form.12 The length of the CAG repeat expansion
in DRPLA within the ATN1 gene correlates strongly with age at onset
(r2 5 0.62, r 5 0.795, p,0.001), with altered clinical phenotype and
life expectancy, with longer repeats being linked to earlier onset and
more severe disease phenotype.1,6,9 Mean age at death is 49 years
(range 18–80 years), median time from disease onset to death is
15 years, and life expectancy is inversely correlated with CAG repeat
length (r 5 –0.89, p,0.001).9 Functional impairment is also inversely
correlated with CAG repeat length, such as the age at which an indi-
vidual becomes wheelchair bound (r 5 –0.87, p,0.001) or artificial
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feeding is required (r 5 –0.9118, p 5 0.0013).6,9,11 In contrast, there is
no direct relationship between CAG repeat length and the rate of
disease progression.9 Pneumonia and less commonly status epilepticus
represent the most common causes of death.9 A summary of common
clinical characteristics and their frequencies in patient populations is
shown in Table 1.
Clinical diagnosis is frequently challenging, with case reports
illustrating confounding factors such as family history of another
neurodegenerative disease13 or non-specific age-associated neuroima-
ging findings.14 In childhood, features of delayed developmental
milestones and seizures have a broad differential diagnosis, while in
adolescence and early adulthood psychiatric symptoms such as irri-
tability, depression, and psychosis may be the presenting features.15–19
Late-onset DRPLA presented as isolated cerebellar ataxia in 50%
individuals and ataxia with or without dementia in 70% individuals
in a recent elderly-onset (.60) case series.14 Differential diagnosis is
Figure 1. Flow Diagram Summarizing the Steps Involved in the Literature Search.
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therefore broad, making diagnosis of DRPLA difficult in the absence
of a known family history of the disease. In addition, neuroimaging
findings can be non-specific,14 with clinical mimics including HD and
the genetically determined SCAs (e.g., SCA1, 2, 3, and 7).13,20
Longer CAG repeat lengths of >65 are often found in patients
with a progressive myoclonus epilepsy (PME) phenotype of DRPLA
consisting of generalized seizures, myoclonus, and progressive intel-
lectual disability, and these individuals typically present before the age
of 20 (juvenile-onset DRPLA).6,9,11 In a recent case series with partially
complete phenotypic data for nine individuals with repeat lengths
>62 and onset before 13 years of age, nine had epilepsy, eight had
intellectual disability, and six exhibited myoclonus.11 Patients with the
adult-onset (age > 20) or non-PME phenotype invariably harbor
shorter repeat lengths of ,65 repeats and present with ataxia, choreo-
athetosis, dementia, and psychiatric features, with seizures being a rare
presenting complaint as shown in reviews of DRPLA cases of non-
Asian6 and supported by significant differences between the above
clinical features between ,65 and >65 repeat allele carriers of Asian
ancestry9 (Figure 2). In addition to genetic testing to confirm diagnosis,
a contemporary study found that the age at which hypoalbuminemia
occurred in DRPLA patients inversely correlated with CAG length in
eight of nine individuals (p,0.01), indicating a potentially useful
biomarker for future clinical trials.21
Epidemiology
DRPLA is most commonly recognized in populations of Japanese
ancestry, with an incidence of 2–7 per million.7,8,22,23 DRPLA is
thought to occur at lower rates in non-Asian populations, although
these estimates are based on the evaluation of cohorts diagnosed with
SCA and may therefore represent an underestimation of DRPLA
prevalence.7 Worldwide the prevalence of SCAs is 2.7 per 100,000,24
and within these cohorts the highest frequency of DRPLA is seen
among Japanese groups (7–20%), with lower rates in other Asian
populations (Singapore, 6%; Korea, 3%).25 In European populations,
DRPLA has a frequency of 2–4% in Portuguese SCA families,8 0.25–
1% in other SCA samples of European descent,23,26,27, and 0.14–3.1%
in Latin-American SCA cohorts.25,28 However, these estimates may be
higher in some populations, potentially because of a higher proportion
of ‘‘high-normal’’ repeat lengths or sampling variation.7 Longer repeat
lengths appear more commonly in populations of Japanese origin than
in Caucasians.29 There are no reported differences in disease char-
acteristics between populations such as the incidence of adult-onset
and juvenile-onset cases, although cohort sizes in some populations
remain small.6
Genetics
The atrophin-1 gene (ATN1), located on chromosome 12p13.31,
encodes a transcriptional co-repressor widely expressed in the central
nervous system and elsewhere in the body.30 ATN1 mutations are
inherited in autosomal dominant fashion, with the CAG repeat
responsible for DRPLA present in exon 5, and is typically present at
#35 repeats. Repeat length alleles of .20 are uncommon and con-
sidered mutable normal alleles, with one allele.20 repeats in a sample
of 177 Caucasian families with mixed SCAs.1,11,29 Such alleles may be
at higher risk for future intergenerational expansion.8,23,26 CAG repeat
lengths differ between populations, such as a .40 repeat length allele
frequency of 20% in families with SCA of Japanese ancestry versus 0%
in Caucasian families (p,0.0001).29 Repeat lengths >48 demonstrate
a fully penetrant clinical phenotype, while alleles of 35–47 repeat
length are incompletely penetrant and have been associated with a
milder DRPLA clinical phenotype in a small number of cases.1,6,11,31
There is one report of an asymptomatic individual aged 81 with a
repeat length of 51.31
DRPLA, in common with other microsatellite repeat disorders,
shows genetic anticipation whereby disease symptoms occur earlier
and more severely generation on generation. Previous studies have
provided estimates of CAG repeat length (median and range)
dependent on age at onset of symptoms: ,21 years (68 repeats; range
63–79), 21–40 years (64 repeats; range 61–69), .40 years (63 repeats;
range 48–67). This phenomenon is thought to be driven by CAG
repeat expansion in the gametes, particularly in spermatogenesis,
as anticipation is more pronounced on paternal inheritance. A small
number of DRPLA cases occur in the absence of any family history of
the disease, suggestive of a de novo repeat expansion from the normal or
intermediate range into the disease-causing range. The factors driving
these cases are unknown.
Expanded polyglutamine (poly-Q) repeats are characteristic of other
autosomal-dominant neurodegenerative disorders such as HD and six
Figure 2. Schematic Representation of the Differences in Clinical Symptomatology with Variation in Age at Onset. This is a schematic
representation of the variation in more clinical phenotypic presentation between those with juvenile symptom onset (,20 years), and those with adult-onset disease
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of the SCA disorders, which also demonstrate features of de novo
expansion and genetic anticipation.30,32–34 CAG repeats can expand
or contract during gametogenesis; therefore, a non-pathogenic sized
CAG repeat may expand and become a de novo pathogenic allele in an
offspring.6,7 Alternatively, a disease causing a CAG repeat may expand
in subsequent generations leading to an earlier-onset and more severe
disease: the phenomenon of anticipation,6,7,35 which is greatest during
paternal transmission.4–6 Both phenomena may have a role, with a
founder Asian haplotype either expanding to other population groups,
or the CAG expansion within these groups arising due to the de novo
phenomenon.6,7,23
Models
Although CAG repeat expansion disorders are all driven by similar
expanded repeats in the DNA that result in central neurodegeneration,
these repeats are in genes encoding different, unrelated proteins and
so it is unsurprising that they induce variable clinical syndromes
associated with different neuropathologies.30 Invertebrate models of
neurodegeneration in DRPLA include the fruit-fly Drosophila melano-
gaster, where the introduction of a human disease allele causes age-
dependent neuronal loss, potentially due to defects in lysosomal
autophagy, and accumulation of the poly-Q repeat protein.30 Homo-
zygous Atn1 knockout mice are viable, without obvious phenotype.36
There are several transgenic mouse models of DRPLA, one of the
first involved introducing a single mutant copy of human ATN1 with
a 65 CAG repeat-length human mutant allele.37 These mice showed
tremor, ataxia, and seizures with premature death; however, although
there was widespread distribution of the mutant protein with neuronal
intranuclear inclusions (NIIs) there was no clear neuronal loss or
macropathology.37
A distinct murine model, involved introduction of a 76 CAG
repeat human disease allele into background wild-type lineage (Q76).
However, in spite of widespread neuronal intranuclear accumulation
(NIA) of mutant protein, initially in an anatomical pattern similar to
DRPLA, these mice exhibited no clear neurological phenotype and did
not form NIIs.38,39 They did however develop a cognitive phenotype
with deficits in spatial learning and memory.40 The same background
murine lineage was used to produce a model with a much longer
repeat length, 129 CAG repeats (Q129), with a repeat of this length
demonstrating features more akin to that seen in humans, including
myoclonus, ataxia, epilepsy, and weight loss that progressed rapidly to
death within 16-weeks.38,39 NIIs appeared, although some time after
symptom onset, and although brain weight and cortical thickness of
the Q129 mice was reduced there was no indication of astrocytosis or
neuronal loss.38,39 Further models with varying repeat lengths have
been generated from this lineage and show that CAG repeat length
correlates with disease severity, as in DRPLA.40 These mouse models
suggest that NIA forms an important pathological marker in DRPLA
and occurs before symptom onset, that pathology is widespread within
the nervous system, although DRPLA anatomical areas are affected
preferentially, and that neuronal atrophy and dysfunction are the
hallmarks of the disease.38,39
In vivo conditional knockdown of an atrophin-1 interacting gene, Lsd1,
in mice has indicated a role for Atrophin-1 in regulating neuronal
progenitor proliferation, a process that can be influenced by the LSD1
inhibitor tranylcypromine. In vitro cellular models have shown a neuronal
accumulation of mutated cleaved products and that longer repeat length
polyglutamine tracts are degraded more slowly than normal repeat
lengths.41,42
Amelioration or reversal of pathology has not been shown in
DRPLA models yet; however, there have been promising findings
from HD.43 The growing field of allele specific gene-silencing tech-
nologies include allele-specific oligonucleotides (ASOs) and less-specific
methods of RNA interference, such as small-hairpin RNA (shRNA).
The latter has been shown to reduce levels of mutant huntingtin in vitro
and in vivo in a transgenic mouse model of HD, with improvement of
motor function.44,45 CRISPR/Cas technology, which allows in vitro or
in vivo genome editing, has also been shown to reduce levels of both
mutant and wild-type huntingtin in a transgenic mouse model of HD
with improvement of motor function.43
Neuropathology
Post-mortem neuropathological findings in DRPLA include an
overall smaller neuraxis, with neuronal loss and astrocytosis in the
dentatorubral and pallidoluysian systems, with intrafamilial variability
of neuroimaging findings being reported.46 The lateral segment of
the globus pallidus is the area most greatly affected by neuronal loss,
with the dentate nucleus and subthalamic nucleus affected to a lesser
extent.2 In the red nucleus, astrocytosis is more prominent than
neuronal loss, and in all affected areas neurons can appear swollen
or shrunken.2 A single case report described severe cerebral white
matter damage without axonal loss and mild atherosclerotic changes,
although white matter findings have not been widely reproduced
elsewhere.47 There are no published comparison studies of neuro-
pathological findings between adult-onset and juvenile-onset DRPLA;
however, a family study of a father and son that showed overall similar
neuropathological findings for other cases of DRPLA exhibited
marked frontal lobe and pontine atrophy in the juvenile-onset case
that was postulated to contribute to the severe cognitive deterioration
and epilepsy observed.46
DRPLA is one of a number of CAG repeat disorders that exhibit
NIIs, with some debate as to whether these represent a key pathogenic
feature, or are unrelated to the primary pathological process, poten-
tially representing a failed neuroprotective process.48 Immunohisto-
chemistry of DRPLA post-mortem brains using an antibody aimed
at identifying polyglutamine stretches shows wide variation in the
deposition of mutant protein, from diffuse intraneuronal accumulation
(NIA) to densely packed areas of mutant protein within the nucleus of
affected neurons (NII).38,49 NIIs are spherical, non-membrane bound
structures that are eosinophilic, contain a mixture of granular and
filamentous structures, are ubiquitinated, and contain the mutant
ATN1 protein.49 Nuclear pathology and nuclear intranuclear inclu-
sions are widespread in the CNS, although some regions, such as the
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hippocampus, appear to be spared, with some debate as to whether
these inclusions are protective or pathological to the neuron.49,50
Neuroimaging
Brain MRI findings are variable and many case reports report only
mild or non-specific changes in the early-stage of disease.10,18,19,51–53
There are only two small studies of DRPLA cohorts (n 5 10,
.60 years of age; n 5 3, aged 39–46 years) and these have identi-
fied characteristic findings in later disease, including brainstem and
cerebellar atrophy and high-intensity T2/fluid-attenuated inversion
recovery weighted signal in the cerebral white matter, thalamus, and
brainstem.14,54 Other imaging studies have used varying sequence
protocols on individual cases10,17,20,47,52 or small pedigrees,16,46 with
inconsistent findings ranging from small vessel disease to more typical
cerebellar and brainstem atrophy, and cerebellar and supratentorial
white matter changes with leuokoencephalopathy, in later disease. An
individual case report highlighted the potential utility of susceptibility
weighted imaging in DRPLA, with the possibility of iron or other cation
deposition in susceptible areas. However, further and larger studies are
required to determine whether this modality provides diagnostic value.52
Figure 3 shows the common MRI features of DRPLA.
The use of imaging to distinguish DRPLA from other clinically
similar disorders is challenging. In late-onset disease, in particular,
isolated atrophy of the brainstem and cerebellum increases the like-
lihood of more common diagnoses being made (e.g. alcohol-induced
cerebellar degeneration), and imaging may show no supportive fea-
tures in an elderly population.14 The SCAs and the cerebellar variant
of progressive supranuclear palsy (PSP-C) often have similar imaging
features to those with DRPLA; however, a single study (n515) iden-
tified increased signal in the brainstem and thalamus as a useful
marker for identifying DRPLA.55 Few functional imaging studies have
been undertaken, with no common disease-specific findings to date.
However, striatal glucose hypometabolism was observed in two
individuals with juvenile-onset DRPLA, which may warrant further
investigation in a larger cohort.53
Neurophysiology
There are few reported electrophysiological studies performed on
patients with DRPLA, with only one retrospective cohort study of 12
juvenile-onset individuals with video-electroencephalography (EEG)56
and the remainder being individual case studies.10,20,56 The seizure
types observed in individuals with DRPLA vary widely and are not
specific for the disorder. For example, a retrospective cohort study in
juvenile-onset DRPLA found that half (six out of 12) exhibited
generalized seizures and/or focal seizures, with slightly fewer atypical
absence seizures (five out of 12), and myoclonic seizures (four out of 12),
and one individual exhibited an atonic event.56 Reported EEG evidence
so far indicates that myoclonus is likely to be cortical.10,56 Seizure
semiology also typically evolves with early features of short-lived
generalized seizures, with subsequent focal seizures and focal seizures
with secondary generalization.10,56 EEG abnormalities have also been
detected in the inter-ictal period, with evidence of frontal intermittent
high-amplitude delta activity.13
Diagnosis
No established clinical diagnostic criteria have been established
for DRPLA, with the genetic diagnosis typically made during the
investigation of symptomatic individuals.1,51 Diagnostic genetic testing
should be considered in any individual with an autosomal dominant
pattern of family history involving cognitive impairment, dementia, or
movement disorder.7 Consensus guidance on testing within adult-onset
ataxia for DRPLA focuses on clinical findings, Asian ancestry, and
family history as being important factors to consider.3 Family history
can identify neurological presentations with overlapping clinical features,
such as atypical Parkinsonism with cerebellar ataxia, Parkinsonism
dementia, and cerebellar atrophy. 10,57
Figure 3. Example of Magnetic Resonance Imaging Findings in Dentatorubral-pallidoluysian Atrophy. (A) Sagittal T1-weighted image demonstrating
global cerebral atrophy, with more marked cerebellar atrophy. (B) Axial T1-weighted image demonstrating bilateral periventricular white-matter lesions.
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Diagnosis may be most difficult in an late-onset adult DRPLA
where other differential diagnoses are more common, and the clinical
presentation may be less typical;14 when isolated ataxia is the sole
clinical finding, more common causes of ataxia are likely to be
considered (e.g. a background of alcohol excess), potentially resulting
in DRPLA not being considered during the diagnostic work-up.1
Genetic testing is typically via polymerase chain reaction amplification
across the ATN1 CAG repeat region followed by gel or capillary
electrophoresis, which identifies 100% of pathogenic expansions of
>48 CAG repeats.1 Although next-generation sequencing technolo-
gies are promising they have not been widely used or validated for the
ATN1 repeat expansion and diagnosis of DRPLA, and repetitive
genomic elements remain problematic to assay via short-read next
generation sequencing technologies.58–60
Management
The clinical management of those diagnosed with DRPLA is
predominantly supportive within the context of a multidisciplinary
team. Genetic counseling is ideally undertaken early to ensure families
are aware of the autosomal dominant nature of the disease, to discuss
predictive testing and potential means of family planning.1 EEG
investigation is indicated in the context of the clinical suspicion of
seizures, and neuropsychological assessment for evidence of dementia
or psychiatric disturbance, particularly when deciding on psychological
support or psychotropic medication.1
There are no clinical trials assessing the efficacy of different anti-
epileptic medications in treating seizures in DRPLA. Myoclonic
seizures can be managed with carbamazepine or phenytoin, unlike
with other forms of myoclonic epilepsy, while sodium valproate,
perampanel, and zonisamide have been used in the treatment of
generalized seizures.10,51,56 Case reports describe the use of various
combinations of anticonvulsants in specific circumstances, but it is
unclear whether these regimens are more broadly useful. For example,
a 17-year-old male diagnosed with juvenile-onset DRPLA exhibit-
ing segmental myoclonus, gait ataxia, and several daily atonic falls
improved with the addition of levetiracetam to sodium valproate,
zonisamide, and taltirelin (2,500 mg, 1,000 mg, 200 mg, and 10 mg
per day, respectively),10 and a bedbound, non-verbal 9 year old with
frequent myoclonic and seizures and generalized tonic–clonic seizures
showed gradually improved ambulation and communication (but no
change in seizure frequency) with the addition of perampanel to
lamotrigine, sodium valproate, clobazam, and phenobarbital (0.4 mg,
100 mg, 600 mg, 20 mg, and 90 mg per day respectively).51
Choreoathetoid and dystonic movements have been managed with
tetrabenazine, risperidone, bromazepam, and gabapentin (no doses
given).47 Consensus European guidelines advise that riluzole (100 mg/
day) is likely effective in reducing ataxia symptoms for adult ataxias
regardless of etiology, with a mean decrease of 7 points (.5 points was
deemed clinically relevant) on the International Cooperative Ataxia
Rating Scale after 8 weeks (Class II evidence).3,61,62 There is weaker
evidence for the use of amantadine 300 mg/day for ataxia.3,63
Education, physiotherapy, occupational therapy, and environmental
adaptation may also be needed at different disease stages. Specialist
palliative care input is recommended throughout the disease course,
with evidence suggesting particular importance later in disease course.1,3
A summary of case reports and clinical trials detailing response to
treatments in DRPLA and cerebellar ataxia is shown in Table 2.
Future directions
DRPLA forms one of a wider spectrum of CAG repeat expansion
diseases, including HD, some SCAs, and spinal and bulbar muscular
atrophy.32 DRPLA shares similarities with HD including that the
clinical and genetic differences between juvenile-onset and adult-onset
DRPLA remain intriguing and unexplained, although extrapolation
from HD literature points towards a combined loss-of-function and
increasingly toxic gain-of-function against the remaining normal allele
with increasing repeat length.12 HD is the most widely studied CAG
repeat expansion disorder and developments in gene silencing via
RNA interference (RNAi) include an antisense oligonucleotide to
huntingtin that alleviates disease in a mouse model.64 In vitro and in vivo
studies have shown allele-specific RNA interference of multiple alleles
is possible within the central nervous system.65
Intrathecal administration of an antisense oligonucleotide directed
towards huntingtin is in phase 2 clinical trials for HD, demonstrating
a dose-dependent reduction in the overall levels of the mutant protein
in cerebrospinal fluid, although the full results of this initial phase of
work are yet to be published.66 Similar approaches might be adopted
to treat DRPLA. Previous success with intrathecal ASO therapy in
neurodegenerative disease has been seen with spinal muscular atrophy,
with higher levels of synthesis of the wild-type allele, and improved
clinical motor function in phase 3 trials, resulting in an expanded access
program for appropriate patients.67,68 Gene-replacement therapy via an
adenovirus vector has also shown promise in this disorder.69 Given the
rarity of DRPLA it is more likely that therapeutic advancements will
arise through the understanding of other neurodegenerative and CAG
repeat expansion disorders. At present, optimized clinical management
includes a timely diagnosis and access to the multidisciplinary team, as
well as the resources needed for ongoing care.
Discussion
Clinical diagnosis of DRPLA in the absence of known family history
of the disease remains challenging within the context of neurodegen-
erative movement disorders, is currently intractable to medical treat-
ment and causes significant disability for those diagnosed with the
disorder. Cohort studies to date are underpowered to draw com-
prehensive conclusions of the true allelic spectrum that causes clinical
symptoms, characteristic neuroimaging findings, and responses to
current treatments. Larger scale, collaborative international studies are
required, and would provide an opportunity for further understanding
of this rare disorder, making use of next-generation genetic sequencing
technologies, standardized neuroimaging pipelines, and fostering an
environment for future clinical trials. As described above, there are
promising developments in the discovery of disease-modifying therapies
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for other neurodegenerative disorders, which may be able to be trans-
lated to DRPLA in the future.
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